Welcome. I'm Dr. Vinay Prasad. I'm a hematologist, oncologist, and I'm associate professor of medicine at the University of California, San Francisco. In my professional life, I see patients, I teach trainees, and I do research in health care policy. This is plenary session.

Plenary session is a podcast at the intersection of medicine, oncology, and health policy,

and you're listening to Season 3. On this week's episode, this week on Plenary Session, I'm joined

by Luke Morris. He's a surgeon, he's a professor at Memorial Sloan Kettering Cancer Center.

He is going to talk about his new paper on tumor mutational burden.

Does it predict who responds to cancer immunotherapy?

Does it vary tumor to tumor?

This is a topic that many of you all may know I'm deeply interested in.

I participated as one side of a two-sided debate

in the annals of oncology last year. And let's see. Let's see what the new data shows. You won't

want to miss this discussion. If you like this podcast and want more content, follow me on

Twitter at Viprasad MDMPH. Check out the YouTube channel, Vinayprasad, MDMPH.

Patreon backers will get access to the slides for lectures I give on plenary session.

Want to hear from us?

Email us your question at plenary session, and I'm joined by Luke Morris.

Luke Morris is a surgeon at Memorial Sloan Kettering Cancer Center.

And I dare say he's a friend of mine.

And he's a friend of the show.

Dr. Morris, I think the truth has come out.

I've admitted something.

So it's a really, it's really a pleasure to have you on this podcast.

Big, yeah, big admirer of the show.

...